CompletedPhase 3

Evaluation of Fontan-associated Hepatic Stiffness and the Efficacy of Udenafil in Reducing Liver Stiffness

United States, Canada88 participantsStarted 2018-02-20

Plain-language summary

A study to evaluate the efficacy of MZ101 therapy in reducing liver stiffness.

Who can participate

Age range

12 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Enrollment in on-going Phase 3 Open-Label Safety Study
. Informed assent from subject, informed consent from parent/legal guardian as appropriate

Exclusion criteria

. Non-enrollment in the on-going Phase 3 Open-Label Study
. Subjects with contra-indications for MRI (these subjects will be excluded from the MRI component of this study)
. Other exclusionary criteria will match those used for the Open-Label Safety Study

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Effect of Udenafil 87.5 mg BID Treatment on Liver Stiffness in Udenafil Continuation and Naive Groups After 52 Weeks, as Determined by Ultrasound Shear Wave Elastography

Timeframe: 52 weeks

Effect of Udenafil 87.5 mg BID Treatment on Liver Stiffness in Udenafil Continuation and Naive Groups After 52 Weeks, as Determined by Magnetic Resonance Elastography

Timeframe: 52 weeks

Trial details

NCT IDNCT03430583

SponsorMezzion Pharma Co. Ltd

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2020-09-15

Results submitted2025-08-24

View on ClinicalTrials.gov More Single Ventricle Heart Disease trials

Who can participate

Age range

12 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Enrollment in on-going Phase 3 Open-Label Safety Study
. Informed assent from subject, informed consent from parent/legal guardian as appropriate

Exclusion criteria

. Non-enrollment in the on-going Phase 3 Open-Label Study
. Subjects with contra-indications for MRI (these subjects will be excluded from the MRI component of this study)
. Other exclusionary criteria will match those used for the Open-Label Safety Study

What they're measuring

Effect of Udenafil 87.5 mg BID Treatment on Liver Stiffness in Udenafil Continuation and Naive Groups After 52 Weeks, as Determined by Ultrasound Shear Wave Elastography

Timeframe: 52 weeks

Effect of Udenafil 87.5 mg BID Treatment on Liver Stiffness in Udenafil Continuation and Naive Groups After 52 Weeks, as Determined by Magnetic Resonance Elastography

Timeframe: 52 weeks